Evogene (EVGN) AI Stock Analysis

• Market Cap: $10.90M
• Dividend Yield: N/A
• Average Volume (3M): 115.16K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.88
• Revenue Growth: -28.72%
• EPS Growth: 43.01%
• Country: US
• Employees: 117
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.50
• Shares Outstanding: 8,716,410
• 10 Day Avg. Volume: 235,429
• 30 Day Avg. Volume: 115,158
• PEG Ratio: 0.01
• Price to Book (P/B): -7.34
• Price to Sales (P/S): 1.25
• P/FCF Ratio: -0.52
• Enterprise Value/Market Cap: 1.48
• Enterprise Value/Revenue: 2.40
• Enterprise Value/Gross Profit: 5.13
• Enterprise Value/Ebitda: -1.37
• 1Y Price Target: $3.50
• Price Target Upside: 180.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 44 Neutral
• Price Target: $1.00 ▼(-20.00% Downside)

Evogene's overall stock score is primarily driven by its weak financial performance, which is the most significant factor. Technical analysis shows a neutral trend, but the valuation remains unattractive due to ongoing losses. The earnings call provided some positive strategic updates, but these are not factored into the score calculation.

Positive Factors

Strategic Shift to AI

The shift to AI-driven innovation, particularly with ChemPass AI, positions Evogene to leverage cutting-edge technology for growth in pharmaceuticals and agriculture, enhancing its competitive edge and market relevance.

Partnership with Google Cloud

The partnership with Google Cloud enhances Evogene's AI capabilities, potentially accelerating innovation in drug discovery and agriculture, strengthening its market position and technological leadership.

Cost Reduction and Efficiency

By reducing R&D and marketing expenses, Evogene is improving operational efficiency, which can lead to better financial health and sustainability, allowing for reinvestment in strategic areas.

Negative Factors

Declining Revenue Growth

Declining revenue growth indicates challenges in market penetration and product adoption, potentially impacting long-term financial stability and necessitating strategic adjustments.

High Leverage and Solvency Risks

High leverage and negative equity pose solvency risks, limiting financial flexibility and increasing vulnerability to economic downturns, which could hinder long-term growth.

Ongoing Cash Burn

Persistent cash burn indicates inefficiencies in operations and a need for external funding, which could strain resources and impact the company's ability to sustain long-term operations.

Evogene Business Overview & Revenue Model

Company Description

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

How the Company Makes Money

Evogene generates revenue primarily through the commercialization of its proprietary technologies and products in the agriculture and pharmaceutical sectors. Key revenue streams include licensing agreements with agricultural companies for its seed traits and technologies, partnerships with industry leaders for co-development projects, and the sale of bio-stimulants and other agricultural solutions. Additionally, the company benefits from strategic collaborations and joint ventures that provide funding and resources for its research and development efforts, further contributing to its earnings.

Evogene Financial Statement Overview

Summary

Evogene's financial health is weak, with improving revenue overshadowed by persistent losses and negative cash flow. The balance sheet shows financial vulnerability, with negative equity and high liabilities. The company needs to address operational inefficiencies and improve its cash flow management to ensure long-term sustainability.

Income Statement

Evogene has shown revenue growth over the years, with a notable increase in 2024. However, the company consistently reports negative EBIT and Net Income, indicating substantial operational challenges. Gross Profit Margin improved significantly in 2024, but the negative Net Profit Margin remains concerning.

Balance Sheet

The balance sheet reflects a high level of liabilities compared to equity, with a negative Stockholders' Equity in 2024, indicating financial instability. The Debt-to-Equity Ratio is not meaningful due to negative equity, while the Equity Ratio has declined sharply.

Cash Flow

The company generates negative Free Cash Flow, with no positive growth trend. Operating Cash Flow remains negative and unstable, indicating cash management issues. There is a reliance on financing activities to fund operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.74M	8.51M	5.64M	1.68M	930.00K	1.04M
Gross Profit	3.15M	5.83M	1.40M	766.00K	163.00K	466.00K
EBITDA	-11.78M	-15.48M	-23.20M	-26.93M	-27.80M	-23.18M
Net Income	-14.25M	-16.48M	-23.88M	-26.64M	-27.79M	-23.37M
Balance Sheet
Total Assets	33.93M	39.86M	51.10M	56.13M	76.30M	71.92M
Cash, Cash Equivalents and Short-Term Investments	11.69M	15.31M	31.06M	35.35M	53.87M	48.23M
Total Debt	12.69M	12.87M	11.51M	11.93M	2.67M	2.44M
Total Liabilities	21.55M	25.03M	22.42M	21.34M	12.88M	15.03M
Stockholders Equity	-3.55M	-1.45M	12.05M	27.93M	54.03M	46.05M
Cash Flow
Free Cash Flow	-18.20M	-20.33M	-22.36M	-24.85M	-25.56M	-20.20M
Operating Cash Flow	-17.62M	-19.70M	-21.58M	-23.68M	-24.84M	-19.51M
Investing Cash Flow	7.34M	9.62M	-4.54M	13.27M	-20.44M	9.41M
Financing Cash Flow	9.16M	4.66M	18.15M	9.34M	30.28M	20.37M

Evogene Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.25
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EVGN, the sentiment is Negative. The current price of 1.25 is above the 20-day moving average (MA) of 1.23, above the 50-day MA of 1.25, and below the 200-day MA of 1.33, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 49.51 is Neutral, neither overbought nor oversold. The STOCH value of 39.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for EVGN.

Evogene Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BOLT	54 Neutral	$11.04M	―	-81.33%	―	-62.68%	23.94%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EVGN	44 Neutral	$10.90M	―	-655.00%	―	-28.72%	43.01%
PHGE	44 Neutral	$15.64M	―	-99.35%	―	―	80.30%
IBIO	42 Neutral	$17.22M	―	-101.52%	―	77.78%	84.08%
KZIA	31 Underperform	$11.69M	―	-3028.18%	―	―	-32.63%
WINT	28 Underperform	$3.81M	―	-169.59%	―	―	85.35%

Evogene Corporate Events

Evogene Partners with Google Cloud to Enhance AI-Driven Molecular Discovery

On September 10, 2025, Evogene Ltd. announced a strategic collaboration with Google Cloud to enhance its AI-driven molecular discovery platform, ChemPass AI. This partnership aims to accelerate innovation in drug discovery and agriculture by leveraging Google’s infrastructure to optimize molecular design across multiple parameters, significantly improving accuracy and efficiency. This collaboration is expected to strengthen Evogene’s market position by expanding its capabilities in delivering innovative solutions to the pharmaceutical and agricultural sectors.

Evogene Announces Q2 2025 Financial Results and Strategic Shift to AI

On August 19, 2025, Evogene Ltd. announced its financial results for the second quarter of 2025, revealing a strategic shift towards AI-driven innovation. The company reported increased revenues of $3.2 million for the first half of 2025, driven by higher seed sales from Casterra, despite a decrease in AgPlenus revenues. Evogene completed the sale of Lavie Bio’s activities and the MicroBoost AI for Ag platform, boosting its cash position and aligning with its strategic focus on ChemPass AI. The company also implemented significant workforce reductions and restructuring plans to enhance operational efficiency and focus on its core technology, positioning itself for growth in the pharmaceuticals and agriculture sectors.

Evogene Shareholders Approve Proposals at Annual Meeting

On August 18, 2025, Evogene Ltd. announced that its shareholders approved all proposals at the annual general meeting, which was held after a one-week adjournment. This approval, in accordance with Israeli Companies Law, signifies a strategic alignment with the company’s goals and may impact its operational strategies and stakeholder interests.

Evogene Updates Proxy Card for August 2025 Shareholder Meeting

Evogene Ltd., an Israeli company, has announced an update regarding its annual general meeting of shareholders scheduled for August 11, 2025. The company has issued a revised proxy card to allow shareholders to vote individually for each director nominee, addressing a previous oversight. This update ensures clarity and consistency for all shareholders, although those voting through Broadridge Financial Solutions or the Tel Aviv Stock Exchange will not be affected by the change.

Evogene Completes Sale of Lavie Bio’s Activities to ICL

On July 8, 2025, Evogene Ltd. announced the completion of a significant transaction involving the sale of most of the activities of its subsidiary, Lavie Bio Ltd., to ICL Group Ltd. This transaction includes the transfer of Lavie Bio’s proprietary technologies and personnel to ICL, while retaining existing strategic partnerships and agreements. This move aligns with Evogene’s strategy to unlock the value of its subsidiaries and is expected to enhance ICL’s capabilities in the ag-biologicals sector, advancing sustainable agricultural solutions.

Evogene Announces Annual General Meeting for August 2025

Evogene Ltd. has announced its upcoming Annual General Meeting of Shareholders, scheduled for August 11, 2025, at its offices in Rehovot, Israel. The meeting will address several key proposals including the re-election and election of directors, amendments to compensation packages, an increase in registered share capital, and the re-appointment of its accounting firm. Shareholders of record as of June 23, 2025, are entitled to vote, and the company’s board recommends voting in favor of the proposals. This meeting is significant for Evogene’s governance and strategic direction, impacting its operational and financial framework.